论文部分内容阅读
目的探讨局限性晚期前列腺癌间歇性内分泌治疗的效果。方法选取局限性晚期(T3a、T3b)前列腺癌患者60例,全雄性激素阻断治疗6～9个月,停药时机为前列腺特异性抗原(PSA)≤0.2ng/ml后,持续3～6个月,以后根据每月PSA的检测结果决定是否再行内分泌治疗。治疗期及间歇期检测血清睾酮值,并行B超检测前列腺体积。结果全部患者完成第1个周期的治疗,50例(83.33%)完成2个周期的治疗,22例(36.67%)完成3个周期的治疗,2例(3.33%)进入到第4个周期的治疗。第一至第四疗程的平均间歇期分别为5.32、5.53、5.36、2.17个月。治疗后6个月和12个月,前列腺体积较治疗前明显缩小(P<0.01),PSA水平较治疗前明显降低(P<0.01)。结论间歇性内分泌治疗是治疗局限性晚期前列腺癌的有效手段。总体安全性和耐受性良好,其近期治疗效果较好。
Objective To investigate the effect of intermittent endocrine therapy in patients with locally advanced prostate cancer. Methods Sixty patients with advanced stage T3a and T3b prostate cancer were treated with all-androgen-blocking therapy for 6-9 months. The timing of discontinuation was 3 to 6 days after the prostate specific antigen (PSA) ≤0.2 ng / ml Month, after the test results according to the monthly PSA decide whether to re-endocrine therapy. Serum testosterone levels were measured during treatment and intermittent periods, and prostate volume was measured by B ultrasound. Results All patients completed the first cycle of treatment, 50 cases (83.33%) completed the treatment of two cycles, 22 cases (36.67%) completed the treatment of three cycles and two cases (3.33%) entered the fourth cycle treatment. The average duration of the first to the fourth course of treatment were 5.32,5.53,5.36,2.17 months. At 6 and 12 months after treatment, the volume of prostate was significantly reduced (P <0.01) and the level of PSA was significantly lower than that before treatment (P <0.01). Conclusion Intermittent endocrine therapy is an effective method for the treatment of locally advanced prostate cancer. Overall safety and well-tolerated, the recent treatment is better.